Tissue factor pathway inhibitor TFPI
Tissue factor pathway inhibitor TFPI
2024-12-30
Tissue factor pathway inhibitor ( TFPI ) is an alternatively spliced anticoagulant protein that primarily inhibits the initial stage of coagulation, preceding thrombin generation. ...
Advancements and challenges in immunocytokines
Advancements and challenges in immunocytokines
2024-12-27
BackgroundImmunocytokines utilize targeted antibodies to concentrate cytokines at tumor sites and have shown potential advantages, such as prolonged cytokine half-life, reduced adv...
The angiogenin VEGFA
The angiogenin VEGFA
2024-12-25
Vascular endothelial growth factor (VEGF) is a homodimeric vasoactive glycoprotein and a key mediator of angiogenesis. The VEGF family consists of five separate gene products: VEGF...
The immunosuppressive molecule B7H4
The immunosuppressive molecule B7H4
2024-12-23
B7H4, V-set domain-containing inhibitor of T-cell activation 1 (VTCN1), also known as B7x, is a member of the B7 family and an inhibitory immune checkpoint. It negatively regulates...
Potent AMA1-specific human monoclonal antibody against Plasmodium vivax
Potent AMA1-specific human monoclonal antibody against Plasmodium vivax
2024-12-20
BackgroundPlasmodium vivax malaria is easily transmitted and remains dormant in the liver, with repeated relapses contributing to the clinical burden. Therefore, new treatments are...
claudin18.2 is a new target for gastric and pancreatic cancer
claudin18.2 is a new target for gastric and pancreatic cancer
2024-12-19
BackgroundRecent advances in the study of CLDN18.2 (Claudin18.2) in gastric and pancreatic cancers have made CLDN18.2 a promising therapeutic target for these two cancers. CLDN18.2...
Angiogenesis regulatory target ANGPT2
Angiogenesis regulatory target ANGPT2
2024-12-17
ANGPT2, also known as ANG-2, is an angiopoietin that binds to TEK/TIE2, competing for ANGPT1 binding sites and modulating ANGPT1 signaling. Ang2 binds to the TIE2 receptor with the...